Title: Estimating Excess Mortality Among People Living with HIV/AIDS During the COVID-19 Pandemic in the USA

Running Head: US Excess Mortality Among PWHA During COVID-19

Lindsay M. HALL[1*], Hamed KARAMI[2], Gerardo CHOWELL[1,3]

[1] Department of Population Health Sciences, Georgia State University, Atlanta, GA, USA

[2] Department of Mathematics and Statistics, Georgia State University, Atlanta, GA, USA

[3] Department of Applied Mathematics, Kyung Hee University, Yongin, 17104, Korea

*Corresponding author. Email: lhall63@student.gsu.edu;

Manuscript Word Count: 3,349

Abstract:

Objectives: To quantify the all-cause excess death rate of people living with

HIV/AIDS (PWHA) during the 2020-2022 COVID-19 pandemic in the United States

(U.S.), including stratifications by sex, age, race/ethnicity, and region.

Design: Using publicly available data from the CDC NCHHSTP AtlasPlus

dashboard, we employed the ensemble n-subepidemic modeling framework

(*SubEpiPredict* toolbox). This flexible modeling framework offers enhanced

precision over static historical-average methods and was used to generate

forecasts of U.S. deaths among PWHA for 2020-2022.

Methods: The models were calibrated using 12 years of pre-pandemic data (2008-

2019), with the median excess death rate calculated as the difference between

forecasted and observed death rates. Results were stratified by age, sex,

race/ethnicity, and U.S. region.

Results: Overall excess deaths among PWHA are estimated at 7,783 [95%

Prediction Interval (PI) 5,098-10,525] crude excess deaths, or a rate of 2.77 [95%

PI 1.81-3.75] excess deaths per 100,000 people, peaking in 2021. Excess death

rates were highest among the following categories: Males (3.39), age group 55-64

(4.94), Multiracial (12.82), and in the Northeast U.S. region (4.12). The absolute

number of excess deaths was highest among the following categories: Males

(4,692), age group 65+ (2,560), Black/African Americans (3,969), and among those

in the South U.S. region (4,025).

Conclusions: These systematic, model-based results reveal stark heterogeneities

among PWHA by exposing recent mortality patterns that may not be captured by

disease-specific mortality reporting alone. These heterogeneous findings can

inform future public health programming and resource allocation and support

tailored interventions for vulnerable populations.

Abstract Word Count: 246

Key Words: HIV, AIDS, n-sub-epidemic, excess mortality, forecast, heterogeneity,

United States, COVID-19

Introduction:

The convergence of two public health crises—COVID-19 and HIV— raises important questions about the intersectional impact of COVID-19 on people living with HIV/AIDS (PWHA), especially within already marginalized groups. Between 2020 and 2022, COVID-19 was listed as an underlying or contributing cause of over one million U.S. deaths—approximately 10.8% of all-cause mortality during that period [1]. Meanwhile, the U.S. mortality rate due to HIV has continued its gradual decline, dropping from 2.6 per 100,000 in 2010 to 1.3 per 100,000 in 2021 [2]. Despite this progress, HIV-related deaths remain disproportionately concentrated among specific populations, particularly males (76%), Black/African American individuals (49%), residents of the South (55%), and adults aged 45 or older (73%) [2]. Examining excess mortality among PWHA during the pandemic— across demographic groups—is essential to understanding potential compounded disparities and to inform more equitable public health responses in the future [3, 4].

Evidence for increased mortality risk among PWHA stems from both biological vulnerabilities—such as potential immunosuppression due to low CD4 cell counts [5,6] —and a range of indirect pandemic effects, including reduced access to care and service interruptions [6, 7]. Several studies report a moderately increased risk of COVID-19 mortality among people living with HIV (PWH) (Hazard ratios of 1.60 to 2.08) [5,8,9].

Overwhelmed healthcare systems diverted resources away from routine HIV prevention, testing, and treatment, while lockdowns and clinic closures disrupted

antiretroviral therapy (ART) adherence and viral suppression efforts—especially in

already resource-constrained communities [10,11,4,7]. These indirect effects likely

contributed to elevated HIV/AIDS mortality during this period—deaths often termed

"second-order deaths"—that may not be fully captured in standard cause-of-death

records [7,12]. Viewed through a syndemic lens, the interaction between HIV and

COVID-19 extends beyond biological co-infection risks. It encompasses

compounding pandemic-related stressors such as visible community health

impacts, social-distancing measures, and reduced access to healthcare. This

framework underscores the multifactorial vulnerabilities faced by PWHA during

overlapping epidemics [13].

Standard cause-of-death records are often insufficient to capture this complexity,

as misclassification and underreporting are common during public health

emergencies [14,12]. In this context, all-cause excess mortality serves as a more

comprehensive metric, capable of capturing both direct and indirect deaths,

including those not explicitly attributed to HIV/AIDS or COVID-19. Previous studies

estimating excess deaths have relied on simple mathematical calculations amongst

people living with HIV (PWH) [6, 7]. However, they do not include deaths coded

among people living with AIDS (PWA), and available stratifications exclude regional

variation. Importantly, all these analyses are restricted to the year 2020, capturing

only the initial phase of the pandemic and omitting the broader compounding

effects of subsequent waves, healthcare disruptions, and policy shifts [15,6,7].

Understanding potential demographic patterns in excess deaths is critical for

identifying disparities, informing recovery efforts, and improving future public health

preparedness. This study addresses that gap by applying n-sub-epidemic modeling

to stratify excess mortality among PWHA in the U.S. by sex, age, race/ethnicity,

and region across the full span of years 2019-2022. Moreover, these results will

serve as a benchmark for existing excess death estimations [6,7] that utilize simple

calculation methods and were limited in scope. Unlike those studies, which

reference historical averages to infer excess deaths, our method compares

forecasted and observed death rates within the same year, allowing for more

precise and timely estimates. Lastly, through this comparison, these results will

also contribute to the growing validation of the modeling framework itself, which

has shown past success on forecasting HIV, COVID-19, and mpox [3,16].

In this study, we employ the ensemble n-subepidemic modeling framework to

estimate excess mortality among PWHA in the U.S. during the COVID-19

pandemic, stratified by sex, age, race/ethnicity, and geographic region. This

approach enables more granular and robust estimates by calibrating to 12 years of

pre-pandemic data and incorporating uncertainty through probabilistic forecasts.

Our results highlight stark heterogeneities in pandemic-related excess mortality

and underscore the importance of tailored equity-informed public health responses.

These estimates serve as a benchmark comparison for published excess death

estimates and inform future emergency-preparedness planning to guide public

health priorities and policies.

Methods:

Data Collection and Preparation

Available yearly all-cause death rates and crude deaths (2008-2022) for PWHA

were obtained from the Center for Disease Control's (CDC) NCHHSTP AtlasPlus

dashboard on February 25th, 2025 (See Footnotes for original data). This database

compiles de-identified HIV/AIDS surveillance data reported to the CDC through the

National HIV Surveillance System (NHSS) by demographic category. Of note, at

the time of analysis, death data for 2022 were considered preliminary and based

on death data received by the CDC as of December 2023. CDC provides additional

data collection details in their *Technical Notes [17].* Since the data is publicly

accessible and de-identified, Institutional review board approval was not required.

Excess Mortality Estimation

To estimate all-cause excess mortality among PWHA during the COVID-19

pandemic, we compared observed deaths during the years 2020–2022 to

counterfactual forecasts generated using the ensemble n-sub-epidemic modeling

framework [16] calibrated to the pre-pandemic period (2008–2019). Specifically, we

computed yearly excess death rates and crude excess deaths by demographic

category.

Models were generated for each death rate by demographic category, as well as a

total death rate for all categories. The original dataset distinguished between all-

cause deaths of PWH versus PWA; this would be expected to have relevance on

mortality rates. Thus, for each demographic category, three separate (3) models

were generated: 1) deaths among PWH, 2) deaths among PHA, and 3) combined

deaths among PLHA. This approach enabled disaggregated and aggregated

assessments across disease indicators.

Models were calibrated using observed death rates from 2008–2019 (baseline

period). Model fitting was conducted using nonlinear least squares, assuming

normally distributed errors, consistent with prior work using annual mortality rates.

We confirmed its suitability through residual diagnostics, which showed no

significant departure from normality. Yearly forecasts of death rates by

demographic category were then generated for 2020-2022. Models include a

median trendline of death rate, as well as a 95% prediction interval (PI) to capture

uncertainty. The 95% prediction interval bounds of the median death rates were

used to compute the excess death rate intervals, using previously established

methodology [18], as described below.

Let $\hat{y}_t$ represent the forecasted death rate per 100,000 population in year t $\in$

{2020, 2021, 2022}, and y_t the corresponding observed death rate. The annual

excess death rate (EDR) is calculated as:

$$EDR_t = y_t - \hat{y}_t$$

where EDR_t denotes the excess death rate per 100,000 people for year t. Since

our forecasted trend $\hat{y}_t$ includes a 95% prediction interval (PI), the lower and

upper bounds of the excess death rate are computed as follows:

$$EDR_t^{LB} = y_t - \hat{y}_t^{UB}, \quad EDR_t^{UB} = y_t - \hat{y}_t^{LB}$$

168   Hence, we ensure that the uncertainty from the forecast is propagated into the

169   excess mortality estimates.

170   To calculate crude excess deaths, each excess death rate was multiplied by the

171   respective population subgroup size N_t given in the original dataset:

$$CED_t = EDR_t \times (N_t / 100{,}000)$$

Lower and upper bounds for crude excess deaths were calculated analogously,

using the corresponding bounds of EDR_t.

It is worth noting that this method allows for quantifying excess mortality across

different demographic groups while incorporating forecast uncertainty. Importantly,

excess death rates are interpreted as the additional deaths per 100,000 people

beyond expected mortality, capturing both direct and indirect effects of the

pandemic.

The n-sub-epidemic framework. A weighted (W) ensemble was derived from the n-

sub-epidemic framework to produce all forecasts [16]. This framework aggregates

multiple asynchronous sub-epidemic models and creates forecasted trajectories. In

this analysis, sub-epidemics are modeled as generalized logistic growth models

and assume a maximum of 2 sub-epidemics in the trajectory to reduce overfitting

and improve stability, given the limited number of annual observations. Model

parameters are estimated using the nonlinear least squares method. To estimate

parameters with known uncertainty, 300 bootstrap samples per model were

generated using the approach described by Hastie et al. [19].

We constructed two ensemble model variations from the top two ranked models

based on Akaike's Information Criterion (AICc). The weighted (W) ensemble model

utilized relative likelihood to determine the weights of the top two ranked models

and the unweighted UW) ensemble model assumed equal weight for the top two

ranked models. Primary results presented in this study are derived from the

weighted ensemble models due to superior calibration performance.

Analyses were performed using MATLAB (R2023a).

Results:

We focus our findings on the weighted (W) ensemble models, which provide better

calibration than unweighted (UW) ensemble models. Nevertheless, the unweighted

(UW) results closely mirrored the trends of weighted (W) but with wider uncertainty

bounds. Unweighted model results are provided in the Supplementary Material.

Overall patterns:

Weighted (W) models forecast a continued decrease in the death rate from HIV,

AIDS, and HIV/AIDS Combined during the pandemic years (Figure 1). However,

observed death rates in the forecast period exceed the weighted (W) model's 95%

PI for all years and all disease indicator categories. The maximum excess death

rate for all disease indicator categories occurred in 2021, with HIV at 1.80 [95% PI

1.23-2.39], AIDS at 1.19 [95% PI 0.80-1.61], and HIV/AIDS combined at 2.77 [95%

PI 1.81-3.75] excess deaths per 100,000 (Figure 2).

Correspondingly, the maximum crude excess deaths for all disease indicator

categories in 2021 were: HIV at 5055 [95% PI 3,444-6,711], AIDS at 3333 [95% PI

2,235-4,512], and HIV/AIDS Combined at 7793 [5,098-10,525] total crude deaths

(Supplementary-Figure 5).

By Sex:

Males had the highest excess death rates in all categories. Weighted (W) models

forecast a continued decrease in the death rate from HIV, AIDS, and HIV/AIDS

Combined (Supplementary-Figure 1) in all sexes. However, observed death rates

in the forecast period exceed the weighted (W) model's 95% PI for all years and

groups. In addition to Males experiencing higher death rates than Females, Males

also experienced higher *excess* death rates than females for all disease indicators.

The maximum excess death rate for all groups occurred in 2021, with Male-

Combined at 3.39 [95% PI 1.69-4.99], Male-HIV at 2.47 [95% PI 1.65-3.35], Male-

AIDS at 1.61 [95% PI 1.06–2.20], Female-Combined 1.56 [95% PI 1.10-2.06],

Female-HIV 0.89 [95% PI 0.59-1.21], and Female-AIDS at 0.66 [0.48-0.86] excess

deaths per 100,000 (Figure 3).

The highest crude excess deaths for all disease indicator categories in 2021 were:

Male-Combined at 4,692 [95% PI 2,338-6,907], Male-HIV at 3,419 [95% PI 2,280-

4,648], Male-AIDS at 2,227 [95% PI 1,471-3,042], Female-Combined 2,220 [95%

PI 1,560-2,930], Female-HIV 1,271 [95% PI 834-1,724], and Female-AIDS at 943

[95% PI 677-1,223] total crude deaths (Supplementary-Figure 6).

By Age:

Older adults experienced the largest excess death burden during the pandemic

period. Weighted (W) models forecast a continued decrease in the death rate from

HIV, AIDS, and Combined HIV/AIDS (Supplementary-Figure 2) for age groups

under age 55, and a continued increase in age groups 55 and above. Observed

death rates in the forecast period exceed the weighted (W) model's 95% PI for

most but not all years and groups.

As shown in Figure 4, age group 13-24 had an excess death rate of 0 for all years,

with minimal positive 95% PI ranges. The age group with the total highest excess

death rate was group 55-64 at 4.94 [95% PI 3.24-6.68] per 100,000 for the

Combined HIV/AIDS group. Notably, the timing of peak excess mortality varied by

age group. Age groups 25-34 and 35-44 for all disease indicator groups had a

maximum excess death rate in 2022. Age groups 45-54, 55-64, and 65+ for all

disease indicator groups had a maximum excess death rate in 2021.

The maximum crude excess deaths for all disease indicator categories occurred in

year 2021 for age group 65+ Combined at 2,560 [95%PI 1,391-3,616] crude deaths

(Supplementary-Figure 7).

By Race:

Black/African American and Multiracial groups experienced the highest race-based

disparities. Weighted (W) models forecast a continued decrease in death rate from

HIV, AIDS, and Combined HIV/AIDS (Supplementary-Figure 3) for American

Indian/Alaska Native, Asian, Black/African American, Hispanic/Latino, and

Multiracial races, and a continued increase in Native Hawaiian/Other Pacific

Islander and White races. Observed death rates in the forecast period for most

years exceeded the weighted (W) model's 95% PI for all races except for Asian

and Native Hawaiian/Pacific Islander races.

As displayed in Figure 5, the maximum excess death rate for all races except for

American Indian/Alaska Native occurred in 2021. Multiracial and Black/African

American races groups had both the highest death rates and highest excess death

rates relative to other races. The race-indicator groups with the overall highest

excess death rate were Multiracial-Combined and Black/African American-

Combined, at 12.82 [95% PI 5.44-20.38] and 11.42 [95% PI 7.07-16.10]

respectively.

The maximum crude excess deaths for all disease indicator categories occurred in

year 2021 for the Black/African American-Combined group at 3,969 [95% PI 2,455-

5,591] crude deaths (Supplementary-Figure 8).

By Region:

The South and Northeast regions bore the highest mortality burden. Weighted (W)

models forecast a continued decrease in death rate from HIV, AIDS, and Combined

HIV/AIDS (Supplementary-Figure 4) for all regions. Observed death rates in the

forecast period for all years exceeded the weighted (W) model's 95% PI for all

regions except for US territories and freely associated states.

Each region's maximum excess death rate occurred in different years, with the

Northeast in 2020, South and West in 2021, and Midwest and US territories and

freely associated states in 2022 (Supplementary-Figure 9). The highest excess

death rate occurred in the Northeast at 4.12 [95% PI 2.76-5.49] in 2020.

Regarding absolute burden, the maximum crude excess deaths for all disease

indicator categories occurred in the year 2021 in the South-Combined group at

4,025 [95% PI 2,450-5,729] crude deaths (Supplementary-Figure 10).

Discussion:

Overall, we estimated excess deaths among PWHA at 7783 crude excess deaths,

or a rate of 2.77 excess deaths per 100,000 people, peaking in 2021. The highest

excess death rates were observed among males (3.39), those aged 55-64 (4.94),

multiracial (12.82), and among those in the Northeast U.S. region (4.12). When

considering the U.S. population at large, crude deaths were highest among the

following categories: Males (4,692), age group 65+ (2,560), Black/African

Americans (3,969), and among those in the South U.S. region (4,025). Generally,

amongst demographic groups in the forecasted pandemic period (2020-2022),

excess death rates and crude estimates peak in year 2021, highlighting the

effectiveness of ongoing dual interventions such as COVID-19 vaccine uptake and

improved receipt medical care for PWHA after COVID-19 pandemic disruptions

settled in 2022 [20].

This analysis uniquely contributes to the literature by quantifying all-cause excess

deaths among PWHA during the COVID-19 pandemic via an n-sub-epidemic

forecasting method—stratified by race, sex, age, and region. The aforementioned

syndemic conceptual framework [13] not only contextualizes the complex interplay

of multiple epidemics but also enhances the interpretive value of our stratified

excess mortality estimates. This analysis of all-cause excess mortality incorporates

deaths that may have been exacerbated by other interacting syndemic risk factors

and thus offers a nuanced quantitative view of how overlapping structural, social,

and biological vulnerabilities may have compounded mortality risks in marginalized

populations. Our stratified results underscore the need for tailored interventions in

future pandemics, especially for populations already burdened by systemic health

disparities.

Demographic Disparities

Our study reinforces well-documented disparities in HIV-related outcomes across

key demographic groups. HIV is well known to have a disproportionate impact on

certain populations, particularly people of color, men who have sex with men, and

transgender women. In 2022, Black Americans made up 40% of people living with

HIV and 43% of HIV-related deaths, despite representing only 12% of the

population. Similarly, Hispanic/Latino individuals comprised 26% of people living

with HIV, exceeding their 19% share of the population [21]. The burden is

especially severe in the Southern U.S., where eight of the ten states with the

highest diagnosis rates are located—driven by limited Medicaid expansion,

healthcare provider shortages, low health literacy, and HIV stigma [22, 21]. These

disparities persist in both infection rates and outcomes, with lower survival rates

and higher HIV-related mortality among Black and Latino populations [21]. Well-

established racial barriers to care have been identified as causes of these

inequities, including disparate access, knowledge, and prioritization to PrEP and

treatment as prevention (TasP) [23,24,25]. These disparities in HIV outcomes

cannot be explained by access to care alone; they are also shaped by entrenched

systemic issues like racism and stigma surrounding HIV [26,25,22].

While estimates of excess death rates—calculated as the difference between

observed and forecasted death rates—may obscure pre-existing demographic

disparities in the forecasted rates, those same disparities can still influence the

observed death rates. In fact, these disparities may be amplified due to the dual

burden of living with HIV/AIDS and experiencing the biological, psychological,

social, and systemic impacts of COVID-19.

Literature Comparisons

Comparisons to previously published estimated excess deaths can be made only

for 2020, since prior research is limited to that year. In comparison to Viguerie et al.

[7], our estimated all-cause crude excess deaths for the year 2020 when limited to

the same demographic groups (i.e., individuals with HIV who are Black/African

American, Hispanic/Latino, or White; all ages, sexes, and U.S. regions), was 3,296

(95% PI: 1,150–5,070) (Supplementary-Figure 8). This represents a 2.1-fold

increase compared to Viguerie et al.'s estimate of 1,550 (95% Confidence Interval

(CI) 1,229–1,877). This difference likely reflects our use of a dynamic modeling

framework calibrated to pre-pandemic trends rather than a simple comparison to a

fixed historical average. When comparing stratifications directly, this ratio stays

generally consistent across sex, age, and race groups, with the upper bound of the

Viguerie et al. CI generally falling near or within our 95% PI lower bound. While the

reasons for this discrepancy in crude death estimates are not immediately obvious,

it should be emphasized that Viguerie et al. estimates 2020 excess death rates by

comparing them to 2018-2019 mortality levels [7].

Only a limited comparison can be made to Zhu et al. [6], who estimate excess

deaths due to COVID-19 specifically among PWH, as opposed to all-cause excess

deaths. This paper includes all demographic groups without stratification, thus our

2020 crude excess death estimate (3,622, 95% PI: 2,050-5,287) reflects a 2.5-fold

increase over their reported estimate of 1,457 (Supplementary-Figure 5). Some

proportion of this discrepancy can be attributed to deaths attributed to non-COVID-

19 causes.

Though Ashraf et al. [15] only examines standard (non-excess) HIV-coded death

rates among PHW through 2020, we found that our models exhibit the same visual

trends across and between categories of sex, age, race, and region.

By applying a validated, model-based forecasting framework to all-cause mortality

data, we extend prior efforts [16] by capturing trends over a longer time horizon

and across key demographic groups. Our stratified estimates offer a reproducible

and transparent point of comparison for future studies evaluating pandemic-related

disparities and syndemic impacts.

Limitations

Our study is not exempt of limitations. First, while this analysis offers a descriptive

view of all-cause excess deaths among PHWA and allows for comparisons

between different demographic categories, it does not offer any control-group

comparisons to the general population. Second, available data did not allow us to

separate all-cause excess mortality into top causes, which prevents further

comparison between HIV/AIDS-related deaths, COVID-19-related deaths, or other

causes. Some sources put (non-excess) death due to HIV/AIDS for specific

population sub-groups into the perspective of other top causes of death both in

PWH and in the general population, mentioning cancer, COVID-19, unintentional

injury, unintentional overdose, heart disease, homicide, and suicide as top sources

of mortality [2]. Third, stratification by co-morbidities (e.g., diabetes, hepatitis,

mental illness) was not feasible due to data limitations, though these conditions

likely influence excess mortality. Future expanded analyses into the breakdown of

causes of excess deaths may allow for even more targeted health policy planning.

Conclusions:

Our results underscore the urgent need to account for the compounded

vulnerabilities faced by PWHA during public health crises. By revealing recent

mortality patterns that may not be captured by disease-specific mortality reporting

alone, our findings help quantify the broader impact of overlapping epidemics.

Understanding how structural barriers and biopsychosocial stressors influence

mortality among PWHA can guide policymakers in designing more equitable

emergency response plans. These findings can inform future public health

programming, resource allocation, and policies to better support those at the

highest risk in future pandemics.

Acknowledgements

1. Author Contributions: L.H. performed data analysis and contributed to manuscript drafting and editing. H.K. assisted with generating figures in MATLAB. G.C. conceived the project, provided general guidance, and revised the manuscript.

2. Conflicts of Interest: The authors declare no conflicts of interest.

3. Sources of Funding: No funding was received for this study.

4. Corresponding Author Contact Information:

    Lindsay Hall, lhall63@student.gsu.edu

5. Research presented at Emory University Summer Institute in Statistics and Modeling in Infectious Diseases (SSMID) Conference. July 2025. Atlanta, Georgia, USA.

6. Note on AI/LLM: The author(s) did not use AI/LLM in any part of the research process and/or manuscript preparation.

7. Original data & analytical code can be found at:

    https://github.com/lhall63/U.S.-Excess-Death-Rates-among-PLHA-during-COVID-19/

References:

[1] Ahmad FB, Cisewski JA. Provisional COVID-19 Mortality Surveillance.

National Center for Health Statistics. 2025.

DOI: https://dx.doi.org/10.15620/cdc/20250305007

[2] Centers for Disease Control and Prevention (CDC) (2021). HIV Mortality,

2021. [PowerPoint slides] Retrieved from https://www.cdc.gov/hiv-

data/media/pdfs/nhss/nhss-surveillance-slideset-mortality-2021.pdf

[3] Bleichrodt, Amanda M.; Okano, Justin T.; Fung, Isaac C.H.; Chowell,

Gerardo; Blower, Sally. The future of HIV: challenges in meeting the 2030

Ending the HIV Epidemic in the US (EHE) reduction goal. AIDS 39(6):p 708-

718, May 01, 2025. | DOI: 10.1097/QAD.0000000000004122

[4] *Chen, J. T., & Krieger, N. (2021). Revealing the unequal burden of COVID-*

19 by income, race/ethnicity, and household crowding: US county versus zip

code analyses. Journal of Public Health Management and Practice,

27(Supplement 1), S43-S56.

[5] Mellor MM, Bast AC, Jones NR, et al. Risk of adverse coronavirus disease

2019 outcomes for people living with HIV. *AIDS.* 2021;35(4):F1-F10.

doi:10.1097/QAD.0000000000002836

[6] Zhu, W., Huang, Y. A., Song, R., Wiener, J., Neblett-Fanfair, R. N., Kourtis,

A. P., & Hoover, K. W. (2023). An estimate of excess deaths among people

with HIV during the coronavirus disease 2019 pandemic in the United

States, 2020. *AIDS (London, England), 37*(5), 851–853.

https://doi.org/10.1097/QAD.0000000000003503

[7] Viguerie, A., Song, R., Bosh, K., Lyles, C. M., & Farnham, P. G. (2024).

Mortality Among Persons With HIV in the United States During the COVID-

19 Pandemic: A Population-Level Analysis. Retrieved January 25, 2025,

from https://stacks.cdc.gov/view/cdc/159428

[8] Boffito, M., & Waters, L. (2021). More evidence for worse COVID-19

outcomes in people with HIV. *The Lancet HIV*, *8*(11), e661–e662.

https://doi.org/10.1016/S2352-3018(21)00272-1

[9] Yang, X., Sun, J., Patel, R. C., Zhang, J., Guo, S., Zheng, Q., Olex, A. L.,

Olatosi, B., Weissman, S. B., Islam, J. Y., Chute, C. G., Haendel, M., Kirk,

G. D., Li, X., Moffitt, R., Akelsrod, H., Crandall, K. A., Francheschini, N.,

French, E., … Mannon, R. B. (2021b). Associations between HIV infection

and clinical spectrum of COVID-19: A population level analysis based on US

National COVID Cohort Collaborative (N3C) data. *The Lancet HIV*, *8*(11),

e690–e700. https://doi.org/10.1016/S2352-3018(21)00239-3

[10] Jewell, B. L., Mudimu, E., Stover, J., Ten Brink, D., Phillips, A. N., Smith, J.

A., ... & Kelly, S. L. (2020). Potential effects of disruption to HIV

programmes in sub-Saharan Africa caused by COVID-19: results from

multiple mathematical models. The lancet HIV, 7(9), e629-e640.

[11] Hogan, A. B., Jewell, B. L., Sherrard-Smith, E., Vesga, J. F., Watson, O. J.,

Whittaker, C., ... & Hallett, T. B. (2020). Potential impact of the COVID-19

pandemic on HIV, tuberculosis, and malaria in low-income and middle-

income countries: a modelling study. The Lancet global health, 8(9),

e1132-e1141.

[12] Woolf S H, Masters R K, Aron L Y. Effect of the covid-19 pandemic in 2020

on life expectancy across populations in the USA and other high income

countries: simulations of provisional mortality data BMJ 2021; 373 :n1343

[13] Shiau, S., Krause, K. D., Valera, P., Swaminathan, S., & Halkitis, P. N.

(2020). The Burden of COVID-19 in People Living with HIV: A Syndemic

Perspective. *AIDS and Behavior*, *24*(8), 2244–2249.

https://doi.org/10.1007/s10461-020-02871-9

[14] Leon, D. A., Shkolnikov, V. M., Smeeth, L., Magnus, P., Pechholdová, M., &

Jarvis, C. I. (2020). COVID-19: a need for real-time monitoring of weekly

excess deaths. The Lancet, 395(10234), e81.

[15] Ashraf, H., Nadeem, A., Ashfaq, H., Fatima, T., Ahmed, S., Nadeem, Z. A.,

& Saleh, A. (2024). Disparities in mortality trends of adults with HIV in the

USA: A comprehensive examination across 2 decades. *Medicine*, *103*(25),

e38570. https://doi.org/10.1097/MD.0000000000038570

[16] Chowell, G., Dahal, S., Bleichrodt, A., Tariq, A., Hyman, J. M., & Luo, R.

(2024). *SubEpiPredict:* A tutorial-based primer and toolbox for fitting and

forecasting growth trajectories using the ensemble *n*-sub-epidemic

modeling framework. *Infectious Disease Modelling*, *9*(2), 411–436.

https://doi.org/10.1016/j.idm.2024.02.001

474 [17] Centers for Disease Control and Prevention (CDC). Technical Notes. 2024.

475  Available at: https://gis.cdc.gov/grasp/nchhstpatlas/main.html. [Accessed 25

476  February 2025].

477 *[18]* Karami, Hamed, Svenn-Erik Mamelund, Alexandra Smirnova, and Gerardo

478  Chowell. *"Global Excess Tuberculosis Mortality During COVID-19: A*

479  *Country-Level Modeling Study of Policy and Development Correlates."*

480  *BMC Public Health, 2025. https://doi.org/10.21203/rs.3.rs-6806070/v1*

481 [19] Hastie T, Tibshirani R, Friedman JH. *The elements of statistical learning:*

482  *data mining, inference, and prediction.* Springer; 2009.

483 [20] Mirzaei H, Moradi Y, Abbaszadeh S, et al. The Impact of COVID-19 on

484  Disruptions of HIV-related Services: A Rapid Review. *Med J Islam Repub*

485  *Iran.* 2022;36:98. Published 2022 Aug 29. doi:10.47176/mjiri.36.98

486 *[21] KFF. (2024, October 15). The impact of HIV on Hispanic/Latino people in*

487  *the United States. KFF. https://www.kff.org/hivaids/fact-sheet/the-impact-of-*

488  *hiv-on-hispanic-latino-people-in-the-united-states/*

489 [22] Sullivan, P. S., Satcher Johnson, A., Pembleton, E. S., Stephenson, R.,

490  Justice, A. C., Althoff, K. N., Bradley, H., Castel, A. D., Oster, A. M.,

491  Rosenberg, E. S., Mayer, K. H., & Beyrer, C. (2021). Epidemiology of HIV in

492  the USA: epidemic burden, inequities, contexts, and responses. *Lancet*

493  *(London, England), 397*(10279), 1095–1106. https://doi.org/10.1016/S0140-

494  6736(21)00395-0

495   [23] Borsa, A., & Siegel, K. (2023). Barriers to Treatment as Prevention

496   Adoption Among Sexual and Gender Minority Individuals Who Have Sex

497   with Men in the United States. *AIDS patient care and STDs*, *37*(5), 268–

498   277. https://doi.org/10.1089/apc.2023.0001

499   [24] Elopre, L., Ott, C., Lambert, C. C., Amico, K. R., Sullivan, P. S., Marrazzo,

500   J., Mugavero, M. J., & Turan, J. M. (2021). Missed Prevention

501   Opportunities: Why Young, Black MSM with Recent HIV Diagnosis did not

502   Access HIV Pre-exposure Prophylaxis Services. *AIDS and behavior*, *25*(5),

503   1464–1473. https://doi.org/10.1007/s10461-020-02985-0

504   *[25] Matacotta, J. J., Rosales-Perez, F. J., & Carrillo, C. M. (2020). HIV*

505   *Preexposure Prophylaxis and Treatment as Prevention - Beliefs and*

506   *Access Barriers in Men Who Have Sex With Men (MSM) and Transgender*

507   *Women: A Systematic Review. Journal of patient-centered research and*

508   *reviews, 7(3), 265–274. https://doi.org/10.17294/2330-0698.1737*

509   [26] Centers for Disease Control and Prevention. (2024). Ending the HIV

510   epidemic in the US: Goals. https://www.cdc.gov/ehe/php/about/goals.html.

511   [Accessed 31 May 2025].